Psychoactives,
Journal Year:
2024,
Volume and Issue:
3(3), P. 411 - 436
Published: Sept. 18, 2024
This
narrative
review
explores
the
utilization
of
psychedelic
states
in
therapeutic
contexts,
deliberately
shifting
focus
from
substances
back
to
experiential
phenomena
which
they
induce,
alignment
with
original
meaning
term
“mind-manifesting”.
provides
an
overview
various
used
modern
settings
and
ritualistic
indigenous
as
well
non-pharmacological
methods
that
can
arguably
induce
states,
including
breathwork,
meditation,
sensory
deprivation.
While
occurrence
mystical
experiences
seems
be
strongest
predictor
positive
outcomes,
literature
this
field
yields
several
other
psychological
processes,
such
awe,
perspective
shifts,
insight,
emotional
breakthrough,
acceptance,
re-experiencing
memories,
certain
aspects
challenging
experiences,
are
significantly
associated
change.
Additionally,
we
discuss
detail
experience-related
changes
metaphysical
self-related
beliefs
their
respective
contributions
observed
outcomes.
We
conclude
a
purely
medical
neurobiological
on
health
is
reductive
should
not
overshadow
significance
phenomenological
understanding
treating
issues
manifest
subjective
realities
human
individuals.
Neuropsychopharmacology,
Journal Year:
2024,
Volume and Issue:
49(4), P. 747 - 756
Published: Jan. 11, 2024
Major
depressive
disorder
(MDD)
is
one
of
the
most
disabling
psychiatric
disorders
in
world.
First-line
treatments
such
as
selective
serotonin
reuptake
inhibitors
(SSRIs)
still
have
many
limitations,
including
a
resistance
to
treatment
30%
patients
and
delayed
clinical
benefit
that
observed
only
after
several
weeks
treatment.
Increasing
evidence
indicates
acute
administration
psychedelic
agonists
5-HT
Journal of Psychopharmacology,
Journal Year:
2024,
Volume and Issue:
38(5), P. 489 - 499
Published: April 28, 2024
Background:
Psilocybin
offers
new
hope
for
treating
mood
disorders
due
to
its
rapid
and
sustained
antidepressant
effects,
as
standard
medications
require
weeks
or
months
exert
their
effects.
However,
the
mechanisms
underlying
this
action
of
psilocybin
have
not
been
identified.
Aims:
To
investigate
whether
has
antidepressant-like
effects
in
mice
potential
are
related
promoted
neuroplasticity.
Methods:
We
first
examined
normal
by
forced
swimming
test
chronic
corticosterone
(CORT)-exposed
sucrose
preference
novelty-suppressed
feeding
test.
Furthermore,
explore
role
neuroplasticity
mediating
psilocybin,
we
measured
structural
neuroplasticity-associated
protein
levels
prefrontal
cortex
(PFC)
hippocampus.
Results:
observed
that
a
single
dose
had
both
healthy
CORT-exposed
mice.
Moreover,
ameliorated
CORT
exposure-induced
inhibition
PFC
hippocampus,
including
increasing
(total
number
dendritic
branches
spine
density),
synaptic
(p-GluA1,
PSD95
synapsin-1)
levels,
BDNF-mTOR
signalling
pathway
activation
(BDNF,
TrkB
mTOR
levels),
promoting
neurogenesis
(number
DCX-positive
cells).
Conclusions:
Our
results
demonstrate
elicits
robust,
which
is
accompanied
promotion
Brain Sciences,
Journal Year:
2025,
Volume and Issue:
15(2), P. 117 - 117
Published: Jan. 25, 2025
Background:
Psychedelics
are
increasingly
recognized
as
a
promising
and
innovative
treatment
strategy
for
several
mental
disorders.
However,
there
is
still
lively
controversy
in
the
medical
community
regards
rationale
of
their
employment,
specifically
indications
potential
dangers.
Methods:
A
comprehensive
literature
search
on
“MEDLINE/PubMed”
“Web
Science”
was
performed
from
inception
to
26
June
2024,
cross-checking
obtained
references.
We
included
all
studies,
i.e.,
both
clinical
preclinical,
that
supplied
original
data.
Results:
initially
total
1083
entries,
813
MEDLINE/PubMed
270
Web
Science.
After
duplicate
elimination,
903
underwent
systematic
selection.
Primary
abstract
screening
yielded
572
candidates
eligibility
assessment
excluded
331
entries
formal
grounds.
Eligibility
led
exclusion
501
titles.
Finally,
70
articles
were
this
review.
Discussion:
Preclinical
evidence
genetic
expression,
histology
behavioral
studies
soundly
consistent
with
psychedelics
possessing
neuroplasticity-inducing
properties.
Despite
methodological
difficulties,
seems
be
inferentially
agreement
preclinical
findings.
it
unclear
whether
“neuroplastic
boost”
induced
by
classic
might
dissociable
psychodysleptic
effects,
thereby
reducing
psychopathological
hazards
implied
these
compounds.
Moreover,
fact
so-called
“relaxation
priors”
should
unconditionally
beneficial
appears
debatable,
further
research
clarify
possible
contraindications
psychedelic
psychoplastogens
within
precision
medicine
perspective.
American Journal of Psychiatry,
Journal Year:
2023,
Volume and Issue:
180(5), P. 340 - 347
Published: May 1, 2023
Over
the
past
decade,
psychedelic
compounds
have
emerged
as
potentially
transformative
therapeutics
for
a
variety
of
intractable
neuropsychiatric
conditions.
However,
historically
most
basic
science
has
utilized
these
probes
to
interrogate
various
endogenous
neurotransmitter
systems-mainly
serotonin
5-HT2A
receptor.
With
renewed
interest
in
utilizing
and
explosion
clinical
trials,
psychedelics
been
purported
treat
many
disorders,
including
depression,
cluster
headaches,
migraines,
anxiety,
obsessive-compulsive
disorder.
It
is
therefore
imperative
understand
biology
pharmacology
behind
their
therapeutic
mechanisms
well
expose
any
potential
pitfalls
widespread
use
treatments.
This
review
covers
latest
advances
understanding
biological
mechanisms,
newest
efforts
drug
discovery,
when
it
comes
this
class
emerging
therapeutics.
Chemical Reviews,
Journal Year:
2023,
Volume and Issue:
124(1), P. 124 - 163
Published: Nov. 30, 2023
Psychedelics
make
up
a
group
of
psychoactive
compounds
that
induce
hallucinogenic
effects
by
activating
the
serotonin
2A
receptor
(5-HT2AR).
Clinical
trials
have
demonstrated
traditional
psychedelic
substances
like
psilocybin
as
class
rapid-acting
and
long-lasting
antidepressants.
However,
there
is
pressing
need
for
rationally
designed
5-HT2AR
agonists
possess
optimal
pharmacological
profiles
in
order
to
fully
reveal
therapeutic
potential
these
identify
safer
drug
candidates
devoid
effects.
This
Perspective
provides
an
overview
structure–activity
relationships
existing
based
on
their
chemical
classifications
discusses
recent
advancements
understanding
molecular
pharmacology
at
structural
level.
The
encouraging
clinical
outcomes
psychedelics
depression
treatment
sparked
discovery
endeavors
aimed
developing
novel
with
improved
subtype
selectivity
signaling
bias
properties,
which
could
serve
potentially
nonhallucinogenic
These
efforts
can
be
significantly
expedited
through
utilization
structure-based
methods
functional
selectivity-directed
screening.
European Journal of Neuroscience,
Journal Year:
2024,
Volume and Issue:
60(2), P. 4063 - 4077
Published: May 21, 2024
Abstract
Psychoactive
substances
obtained
from
botanicals
have
been
applied
for
a
wide
variety
of
purposes
in
the
rituals
different
cultures
thousands
years.
Classical
psychedelics
N,N′‐dimethyltryptamine,
psilocybin,
mescaline
and
various
lysergamides
cause
specific
alterations
perception,
emotion
cognition
by
acting
through
serotonin
5‐HT
2A
receptor
activation.
Lysergic
acid
diethylamide,
first
famous
breakthrough
field,
was
discovered
chance
Albert
Hoffman
Zurich
Sandoz
laboratory
1943,
studies
on
its
psychoactive
effects
began
to
take
place
literature.
Studies
this
area
were
blocked
after
legislation
controlling
use
research
psychedelic
drugs
came
into
force
1967,
but
since
1990s,
it
has
started
be
matter
scientific
curiosity
again
groups.
In
particular,
with
crucial
reports
psychotherapy‐assisted
psilocybin
applications
life‐threatening
cancer‐related
anxiety
depression,
new
avenues
opened
treatment
psychiatric
diseases
such
as
treatment‐resistant
depression
substance
addictions.
An
increasing
number
show
that
very
promising
potential
neuropsychiatric
where
desired
efficiency
cannot
achieved
conventional
methods.
context,
we
discuss
therapy,
encompassing
historical
development,
therapeutic
effects—especially
trauma
disorders
disorders—within
framework
ethical
considerations.
